Clinical Trials in Oncology Handbook 2025

The go-to guide for professionals in the global oncology clinical trials space

  • Complimentary
close

Handbook

We are delighted to announce the arrival of the Clinical Trials in Oncology Handbook 2025 Edition, which offers the best of our speakers summarising the industry at present.  Please view it here.

Comprising of industry-written pieces, the handbook outlines advancements in research and development are putting increasing demands on clinical trial sponsors; with new drugs and medicines in the pipeline addressing some of the most complex and deadly disease areas of today, clinical teams need to keep up to meet the patient and global market requirements and take oncology-based therapy to the next level.Articles you won’t want to miss include:

  • More narrowly defined target patient populations contributing to protocol amendments in oncology clinical trials
  • The application of AI and ML in pharma and biotechnology
  • Crossing the divide: a drug development professional’s experience as a clinical trial participant

Agenda

Expand All

Advisory Board

Select a member to learn more

Back
Cesare Spadoni
Founder And Chief Operating Officer, Oncoheroes Biosciences

Cesare is co-founder and Chief Operating Officer of Oncoheroes Biosciences Inc., a Boston-based biotech company focused on pediatric oncology drug development. Cesare has more than 20 years of experience in the drug development field, in both scientific and commercial roles. Previously, he held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis. Cesare started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest).

Following the death of his first daughter Laura to cancer, Cesare set up aPODD Foundation, a London-based charity focused on accelerating paediatric oncology drug development. As aPODD’s chairman he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations.

Cesare holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest.

Next
Back
Frank Richard
Vice President Medical, Heidelberg Pharma
Next
Back
Stefano Ferrara
Director Of Clinical Science, BeiGene
Next
Back
Fatima Scipione
Vice President, Global Patient Affairs, Blueprint Medicines

Fatima is passionate about elevating the patient voice on a global scale.

She believes that understanding patient experiences and challenges is essential to speeding up the development of life-changing medicines. Further, she advocates in support of patients gaining the skills, courage, and knowledge to navigate through a cancer diagnosis, to make informed decisions, and to ensure they can advocate for and achieve the best care possible.

This fierce passion and commitment to putting the needs of patients first is evident in her decades-long career where she is recognized as an influential global advocate thought leader focused on patient centered research, policy, access, and regulatory impact.

She has held multiple senior management positions in healthcare and is a respected member of the biopharma and cancer communities. Fatima has contributed to numerous publications in partnership with the advocacy community and key academic researchers to advance patient-centered care, as well as being included in the PharmaVOICE 100 in 2014 and receiving the Trailblazer Brand Champion Award from PM3670 in 2015

Next

Sponsors

Select a sponsor to learn more

Enquiry

Contact Us

ADVERTISING OPPORTUNITIES

Conor Taylor

+44 (0)207 936 6870

ARTICLE CONTRIBUTION

Louisa Manning

Program Director

+44 (0)20 766 10552

MARKETING ENQUIRIES

Moona Popal

Marketing Manager

Download Handbook

ADVERTISING OPPORTUNITIES

 

Conor Taylor

 


+44 (0)207 936 6870

ARTICLE CONTRIBUTION

 

Louisa Perry

Head of Oncology Conferences


+44 (0)20 766 10552